Specialty European Pharma launches plenaxis ...( London 26 February. Speciality Euro...),Health
London, 26 February. Speciality European Pharma (SEP) today announced the launch of Plenaxis® in Germany. Plenaxis® is used to treat advanced and metastatic hormone responsive prostate cancer and it causes a rapid and sustained decline in testosterone levels, thereby giving quick control of prostate cancer symptoms. Once the disease is under control, the physician can choose to either keep the patient on Plenaxis® or to stop treatment and recommence once there is evidence of disease activity returning. This is attractive because, on stopping treatment with Plenaxis® the patients testosterone levels will return to the normal range whilst the disease remains under control. In addition to the quick control of testosterone, Plenaxis avoids any testosterone flare and removes the need for concomitant use of anti-androgen therapy.
Commenting on the launch of Plenaxis®, Geoff McMillan, the CEO of SEP, said, Plenaxis® is an important product, both for SEP and for sufferers of prostate cancer. Plenaxis is the first new type of hormone treatment for prostate cancer to be introduced for many years and it gives patients and physicians added control of this disease.
Ken Watters, Chief Medical Officer of SEP added that prostate cancer is an important cause of morbidity and mortality in males over 50 years old. The emerging treatment modalities are especially suited to Plenaxis® with its rapid and sustained disease control and quick testosterone recovery.
'/>"/>
| Contact: Blake Scotland bscotland@ruderfinn.co.uk 020-746-28975 Ruder Finn Public Relations Source:Eurekalert |
Related medicine news :
1. Darwin Enters into Marketing Partnership with Agency Specialty Product Network
2. MarketResearch.com Distributes Key Findings on Global Specialty Medical Beds and Therapeutic Surfaces Market
3. Caris Diagnostics Announces Addition of Leading Dermatopathologist to Expand Subspecialty Expertise
4. Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
5. Fairview Specialty Pharmacy Signs Contract With BioMarin for Distribution of Kuvan(TM)
6. Specialty Blades, Inc. Completes Acquisition of Popper and Sons, Inc.
7. EpiCept Corporation to Present at The New York Society of Security Analysts 11th Annual Biotech & Specialty Pharma Conference
8. Heska to Present at New York Society of Security Analysts Biotech/Specialty Pharma Conference
9. Albemarle Raises Prices of Specialty Aluminas
10. Franklin & Seidelmann Adds 31 Subspecialty Radiologists to Support Growing Demand for Subspecialty Expertise
11. Specialty Underwriters Alliance to Present at 2007 FBR Capital Markets Investor Conference
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |